Regentis Biomaterials Ltd. (NYSE American: RGNT) priced its initial public offering at $8.00 per ordinary share, the Israel-based regenerative medicine company announced. The offering consists of 1,250,000 ordinary shares, generating gross proceeds of $10 million before underwriting discounts and expenses.
The company granted underwriters a 45-day option to purchase up to 187,500 additional shares to cover over-allotments. ThinkEquity serves as the sole book-running manager for the offering.
Trading on the NYSE American is expected to begin December 4, 2025, under the ticker symbol "RGNT." The offering is scheduled to close on or about December 5, 2025, subject to customary closing conditions.
Regentis plans to use net proceeds primarily for development activities, including completion of its pivotal trial and preparation of the PMA submission for GelrinC. The funds will also support corporate purposes including debt repayment and deferred compensation payments.
The company develops tissue repair solutions using its Gelrin platform based on degradable hydrogel implants. Its lead product candidate, GelrinC, is a cell-free hydrogel that forms a temporary implant in the knee for treating articular knee cartilage injuries. GelrinC received CE mark approval in Europe and the company plans to start European commercialization while pursuing FDA approval in the United States.
A Registration Statement on Form F-1 relating to the shares was filed with the Securities and Exchange Commission and became effective November 12, 2025.
